GlycoMimetics, Inc. stock is up 25.93% since 30 days ago. The next earnings date is Mar 27, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 December’s closed higher than November.
GlycoMimetics, Inc. focuses on the discovery and development of novel glycomimetic drugs. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML.